Cargando…

Cannabidiol and Amisulpride Improve Cognition in Acute Schizophrenia in an Explorative, Double-Blind, Active-Controlled, Randomized Clinical Trial

Cannabidiol (CBD), a principal phytocannabinoid constituent, has demonstrated antipsychotic properties in recent clinical trials. While it has also been suggested a promising candidate for the treatment of neurodegenerative disorders, it failed to demonstrate efficacy in cognitive impairments associ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leweke, F. Markus, Rohleder, Cathrin, Gerth, Christoph W., Hellmich, Martin, Pukrop, Ralf, Koethe, Dagmar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117353/ https://www.ncbi.nlm.nih.gov/pubmed/33995015 http://dx.doi.org/10.3389/fphar.2021.614811

Ejemplares similares

Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Emotion, Cognition, and Attention: A Double-Blind, Placebo-Controlled, Randomized Experimental Trial in Healthy Volunteers
por: Woelfl, Timo, et al.
Publicado: (2020)

Cannabidiol enhances cerebral glucose utilization and ameliorates psychopathology and cognition: A case report in a clinically high-risk mental state
por: Koethe, Dagmar, et al.
Publicado: (2023)

Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence
por: Rohleder, Cathrin, et al.
Publicado: (2016)

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
por: Leweke, F M, et al.
Publicado: (2012)

Neural Autoantibodies in Cerebrospinal Fluid and Serum in Clinical High Risk for Psychosis, First-Episode Psychosis, and Healthy Volunteers
por: Bien, Christian G., et al.
Publicado: (2021)

Simultaneous Assessment of Serum Levels and Pharmacologic Effects of Cannabinoids on Endocannabinoids and N-Acylethanolamines by Liquid Chromatography–Tandem Mass Spectrometry
por: Couttas, Timothy A., et al.
Publicado: (2023)

Population pharmacokinetics of Amisulpride in Chinese patients with schizophrenia with external validation: the impact of renal function
por: Li, Anning, et al.
Publicado: (2023)

Current State of Fluid Lipid Biomarkers for Personalized Diagnostics and Therapeutics in Schizophrenia Spectrum Disorders and Related Psychoses: A Narrative Review
por: Couttas, Timothy A., et al.
Publicado: (2022)

Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: a double-blind, placebo-controlled trial
por: Barnes, Thomas R.E., et al.
Publicado: (2018)

Metabolic Profiling of CSF: Evidence That Early Intervention May Impact on Disease Progression and Outcome in Schizophrenia
por: Holmes, Elaine, et al.
Publicado: (2006)

Update on the management of symptoms in schizophrenia: focus on amisulpride
por: Mortimer, Ann M
Publicado: (2009)

Perioperative utility of amisulpride and dopamine receptor antagonist antiemetics-a narrative review
por: Elias, Murad, et al.
Publicado: (2023)

No Acute Effects of Cannabidiol on the Sleep-Wake Cycle of Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study
por: Linares, Ila M. P., et al.
Publicado: (2018)

Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders?
por: Loss, Cássio Morais, et al.
Publicado: (2021)

Cannabidiol Administered During Peri-Adolescence Prevents Behavioral Abnormalities in an Animal Model of Schizophrenia
por: Peres, Fernanda F., et al.
Publicado: (2018)

Case Report: Severe Adolescent Major Depressive Syndrome Turns Out to Be an Unusual Case of Anti-NMDA Receptor Encephalitis
por: Moldavski, Alexander, et al.
Publicado: (2021)

PM391. THE USE OF AMISULPRIDE IN TREATMENT OF PATIENTS WITH RESIDUAL SCHIZOPHRENIA
por: Janjic, Vladimir, et al.
Publicado: (2016)

A cost-utility analysis of Amisulpride and Paliperidone in the treatment of Schizophrenia
por: Abdall-Razak, Ali, et al.
Publicado: (2019)

Hyperprolactinaemia with amisulpride
por: Raj, Rajnish, et al.
Publicado: (2008)

Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial
por: Zhu, Ming-Huan, et al.
Publicado: (2022)

M41. TRAJECTORIES AND PREDICTORS OF OUTCOME IN SCHIZOPHRENIA: THE BENEFICIAL ROLE OF AMISULPRIDE
por: Drosos, Petros, et al.
Publicado: (2020)

Optimizing subjective wellbeing with amisulpride in first episode schizophrenia or related disorders
por: de Haan, Lieuwe, et al.
Publicado: (2023)

Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats
por: Peres, Fernanda F., et al.
Publicado: (2016)

Pharmacovigilance on cannabidiol as an antiepileptic agent
por: Ammendolia, Ilaria, et al.
Publicado: (2023)

Amisulpride induced mania
por: Aggarwal, Ashish, et al.
Publicado: (2010)

Cannabidiol, among Other Cannabinoid Drugs, Modulates Prepulse Inhibition of Startle in the SHR Animal Model: Implications for Schizophrenia Pharmacotherapy
por: Peres, Fernanda F., et al.
Publicado: (2016)

Effects of adjunctive brexpiprazole on sleep-wake and circadian parameters in youth with depressive disorders: study protocol for a clinical trial
por: Carpenter, Joanne S, et al.
Publicado: (2022)

Amisulpride Augmentation in Schizophrenia Patients with Poor Response to Olanzapine: A 4-week, Randomized, Rater-Blind, Controlled, Pilot Study
por: Woo, Young Sup, et al.
Publicado: (2022)

Amisulpride Augmentation in Schizophrenia Patients with Poor Response to Olanzapine: A 4-week, Randomized, Rater-Blind, Controlled, Pilot Study
por: Bahk, W.-M., et al.
Publicado: (2023)

Cannabidiol Treatment for Refractory Epilepsies in Pediatrics
por: Raucci, Umberto, et al.
Publicado: (2020)

Editorial: Cannabidiol Treatment in Neurotherapeutic Interventions
por: Gonzalez-Cuevas, Gustavo, et al.
Publicado: (2021)

Repetitive transcranial magnetic stimulation combined with olanzapine and amisulpride for treatment-refractory schizophrenia
por: Liu, Jin-Ling, et al.
Publicado: (2023)

Amisulpride Reexposure and Tardive Dyskinesia
por: Sidana, Ajeet
Publicado: (2018)

A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans
por: Millar, Sophie A., et al.
Publicado: (2018)

Cannabidiol Reduces Leukemic Cell Size – But Is It Important?
por: Kalenderoglou, Nikoletta, et al.
Publicado: (2017)

Cannabis Contaminants Limit Pharmacological Use of Cannabidiol
por: Montoya, Zackary, et al.
Publicado: (2020)

Cannabidiol markedly alleviates skin and liver fibrosis
por: del Río, Carmen, et al.
Publicado: (2022)

Cannabidiol for neurodegenerative disorders: A comprehensive review
por: Bhunia, Sukanya, et al.
Publicado: (2022)

Cannabidiol (CBD) and Δ(9)-tetrahydrocannabinol (THC) for chronic insomnia disorder (‘CANSLEEP’ trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial
por: Suraev, Anastasia, et al.
Publicado: (2020)

The Functional Networks of Prepulse Inhibition: Neuronal Connectivity Analysis Based on FDG-PET in Awake and Unrestrained Rats
por: Rohleder, Cathrin, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_idn9t4tjjunrvrbar3lgnlrfou